Flowserve Corporation Common Stock vs Liquidia Corporation Common Stock — how do they compare? Flowserve Corporation Common Stock trades at $69.78 (market cap $9.08B), while Liquidia Corporation Common Stock trades at $34.9 (market cap $2.40B). The key difference: Flowserve Corporation Common Stock is far larger — about 3.8× Liquidia Corporation Common Stock's market cap, and Flowserve Corporation Common Stock pays a 1.23% dividend while Liquidia Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Flowserve Corporation Common Stock for 6 Days and Liquidia Corporation Common Stock for 0 Days on average.
| FLS | LQDA | |
|---|---|---|
Market Cap | $9.08B | $2.40B |
Volume | 1,742,251 | 2,857,547 |
Sector | Industrials | Health |
52-Week High | $92.04 | $91.03 |
52-Week Low | $50.41 | $22.02 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $10.67B | $2.30B |
Dividend Yield | 1.23% | — |
Signals from Pluang's Aura AI — not financial advice
FLS trades at $71.47, up 1.16% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q3 2026 results pending. Revenue for 2025 was $4.73 billion, with a net income margin of 8.01%. Recent news includes a new CFO appointment and a quarterly dividend declaration.
The outlook is mixed: strong fundamentals and a consensus price target of $90.75 suggest upside, but technical weakness and a high P/E of 24.9 pose risks. Key opportunities include strategic acquisitions and nuclear market exposure, while headwinds include weak organic sales and rising debt levels noted by analysts.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Flowserve Corporation is a Texas-based manufacturer of engineered flow-control equipment, producing industrial pumps, mechanical seals, valves, and automation products through its Flowserve Pumps Division and Flow Control Division, serving the oil and gas, chemical, power, and water industries in more than 50 countries.
Read more on FLS →Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →